Twist Bioscience expects to go public this week, after raising around $280 million in venture capital funding, but biotech giant Agilent is seeking to make the IPO more difficulthttps://www.axios.com/twist-ipo-agilent-sec-6f5dd7ae-11f4-404d-9e92-57db39b4ebf7.html?utm_source=twitter&utm_medium=social&utm_campaign=organic&utm_content=1100 …
0 replies
1 retweet
2 likes
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.